Global Age-related Macular Degeneration Drugs Market Growth (Status and Outlook) 2025-2031

The global Age-related Macular Degeneration Drugs market size is predicted to grow from US$ 8819 million in 2025 to US$ 11350 million in 2031; it is expected to grow at a CAGR of 4.3% from 2025 to 2031.

Age-related macular degeneration (AMD) drugs refer to drugs used to treat age-related macular degeneration. These drugs are designed to slow or prevent the progression of AMD by inhibiting the formation of new blood vessels, reducing inflammatory responses, and providing antioxidant protection, thereby protecting the patient's vision.

In recent years, with the intensification of the global aging trend and the improvement of people's awareness of eye health, the market size of age-related macular degeneration drugs has continued to expand. From a regional perspective, North America and Europe are the main markets for age-related macular degeneration drugs, each occupying a large market share. Emerging markets such as China are also growing rapidly and are expected to become an important part of the global age-related macular degeneration drug market in the future.

LPI (LP Information)' newest research report, the “Age-related Macular Degeneration Drugs Industry Forecast” looks at past sales and reviews total world Age-related Macular Degeneration Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Age-related Macular Degeneration Drugs sales for 2025 through 2031. With Age-related Macular Degeneration Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Age-related Macular Degeneration Drugs industry.

This Insight Report provides a comprehensive analysis of the global Age-related Macular Degeneration Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Age-related Macular Degeneration Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Age-related Macular Degeneration Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Age-related Macular Degeneration Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Age-related Macular Degeneration Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Age-related Macular Degeneration Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Antioxidants
Anti-inflammatory Drugs
Others

Segmentation by Application:
Wet AMD Treatment
Adjunctive Treatment of Dry AMD
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Regeneron Pharmaceuticals
Roche Holding
Novartis
Bayer
Biogen
Alimera Sciences
Adverum Biotechnologies
Eyepoint Pharmaceuticals
Outlook Therapeutics
Apellis Pharmaceuticals
Amgen

Please note: The report will take approximately 2 business days to prepare and deliver.